user login

Liraglutide Zhuhai Gene-Biocon Biological Technology

60.0 USD
Min. Order: 1 Piece/Pieces
Payment Terms: T/T
Place of Origin: Guangdong

Company Profile

Location: Zhuhai, Guangdong, China (Mainland)
Business Type: Manufacturer

Product Detail

Delivery Date: 7-15days

Product Description

CAS.NO: 204656-20-2

 

Liraglutide 3.0 can reduce glycosylated hemoglobin, and it has been shown to be beneficial to cardiovascular treatment in typeⅡ diabetic patients with atherosclerotic cardiovascular disease with coronary heart disease, ischemic stroke, and peripheral artery disease. 

 

Product Name

Liraglutide

Packing Specification

10g/100g/500g

Appearances

White or off-white powder

Activity: NLT 10Unit/mg

70%~130%

Content: 95.0%~105.0%

95.0%~105.0%

Bacterial Endotoxin

Less than 10 EU/mg

Residual HCP

NMT 10ng/mg

Residual Exogenous DNA

NMT 10ng/dose

Macromolecular Potein

NMT 0.7%

HPLC Purity

>98.0%

Storage Conditions

-15℃ below, protected from light, sealed.

Liraglutide Application

Used to prepare liraglutide formula injection.

 

Liraglutide Insulin Recommended Method

Liraglutide treatment easy dissolved in acidic (pH < 2.5), neutral and alkaline conditions, and can be dissolved and clarified above pH7.0.

 

Insulin Degludec and Liraglutide Transport and Storage Stability

Transportation stability: It is transported in an ice pack to keep it active.

Storage stability: The product can be stored for at least 24 months at -15°C below.

 

Notice and Disclaimer

Pollution should be avoided during operation.

The product should not be used for diagnosis or treatment of animals or humans.

 

If you want to know more about liraglutide in type 1 diabetes, please visit our website.

 

As a biopharmaceutical company, we can offer kinds of Pharmaceutical raw materials for sale, anything you need, please contact us.

 


Post Buying Request